Show simple item record

dc.contributor.authorWisco, Oliver J
dc.contributor.authorMarson, Justin W
dc.contributor.authorLitchman, Graham H
dc.contributor.authorBrownstone, Nicholas
dc.contributor.authorCovington, Kyle R
dc.contributor.authorMartin, Brian J
dc.contributor.authorQuick, Ann P
dc.contributor.authorSiegel, Jennifer J
dc.contributor.authorCaruso, Hillary G
dc.contributor.authorCook, Robert W
dc.contributor.authorWinkelmann, Richard R
dc.contributor.authorRigel, Darrell S
dc.date.accessioned2023-03-03T18:30:21Z
dc.date.available2023-03-03T18:30:21Z
dc.identifier.citationWisco OJ, Marson JW, Litchman GH, Brownstone N, Covington KR, Martin BJ, Quick AP, Siegel JJ, Caruso HG, Cook RW, Winkelmann RR, Rigel DS. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging. Melanoma Res. 2022 Apr 1;32(2):98-102. doi: 10.1097/CMR.0000000000000804. PMID: 35254332; PMCID: PMC8893124.en_US
dc.identifier.eissn1473-5636
dc.identifier.doi10.1097/CMR.0000000000000804
dc.identifier.pmid35254332
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8467
dc.description.abstractCutaneous melanoma (CM) survival is assessed using averaged data from the American Joint Committee on Cancer 8th edition (AJCC8). However, subsets of AJCC8 stages I-III have better or worse survival than the predicted average value. The objective of this study was to determine if the 31-gene expression profile (31-GEP) test for CM can further risk-stratify melanoma-specific mortality within each AJCC8 stage. This retrospective multicenter study of 901 archival CM samples obtained from patients with stages I-III CM assessed 31-GEP test predictions of 5-year melanoma-specific survival (MSS) using Kaplan-Meier and Cox proportional hazards. In stage I-III CM population, patients with a Class 2B result had a lower 5-year MSS (77.8%) than patients with a Class 1A result (98.7%) and log-rank testing demonstrated significant stratification of MSS [χ2 (2df, n = 901) = 99.7, P < 0.001). Within each stage, 31-GEP data provided additional risk stratification, including in stage I [χ2 (2df, n = 415) = 11.3, P = 0.004]. Cox regression multivariable analysis showed that the 31-GEP test was a significant predictor of melanoma-specific mortality (MSM) in patients with stage I-III CM [hazard ratio: 6.44 (95% confidence interval: 2.61-15.85), P < 0.001]. This retrospective study focuses on Class 1A versus Class 2B results. Intermediate results (Class 1B/2A) comprised 21.6% of cases with survival rates between Class 1A and 2B, and similar to 5-year MSS AJCC stage values. Data from the 31-GEP test significantly differentiates MSM into lower (Class 1A) and higher risk (Class 2B) groups within each AJCC8 stage. Incorporating 31-GEP results into AJCC8 survival calculations has the potential to more precisely assess survival and enhance management guidance.
dc.language.isoenen_US
dc.relation.urlhttps://journals.lww.com/melanomaresearch/Fulltext/2022/04000/Improved_cutaneous_melanoma_survival.4.aspxen_US
dc.rightsCopyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleImproved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleMelanoma researchen_US
dc.source.volume32
dc.source.issue2
dc.source.beginpage98
dc.source.endpage102
dc.source.countryEngland
dc.description.versionVoRen_US
refterms.dateFOA2023-03-03T18:30:22Z
html.description.abstractCutaneous melanoma (CM) survival is assessed using averaged data from the American Joint Committee on Cancer 8th edition (AJCC8). However, subsets of AJCC8 stages I-III have better or worse survival than the predicted average value. The objective of this study was to determine if the 31-gene expression profile (31-GEP) test for CM can further risk-stratify melanoma-specific mortality within each AJCC8 stage. This retrospective multicenter study of 901 archival CM samples obtained from patients with stages I-III CM assessed 31-GEP test predictions of 5-year melanoma-specific survival (MSS) using Kaplan-Meier and Cox proportional hazards. In stage I-III CM population, patients with a Class 2B result had a lower 5-year MSS (77.8%) than patients with a Class 1A result (98.7%) and log-rank testing demonstrated significant stratification of MSS [χ2 (2df, n = 901) = 99.7, P < 0.001). Within each stage, 31-GEP data provided additional risk stratification, including in stage I [χ2 (2df, n = 415) = 11.3, P = 0.004]. Cox regression multivariable analysis showed that the 31-GEP test was a significant predictor of melanoma-specific mortality (MSM) in patients with stage I-III CM [hazard ratio: 6.44 (95% confidence interval: 2.61-15.85), P < 0.001]. This retrospective study focuses on Class 1A versus Class 2B results. Intermediate results (Class 1B/2A) comprised 21.6% of cases with survival rates between Class 1A and 2B, and similar to 5-year MSS AJCC stage values. Data from the 31-GEP test significantly differentiates MSM into lower (Class 1A) and higher risk (Class 2B) groups within each AJCC8 stage. Incorporating 31-GEP results into AJCC8 survival calculations has the potential to more precisely assess survival and enhance management guidance.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentDermatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalMelanoma research


Files in this item

Thumbnail
Name:
Improved_cutaneous_melanoma_su ...
Size:
501.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Except where otherwise noted, this item's license is described as Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.